Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3

Nephrology Dialysis Transplantation

Volumn 28, Issue 4, 2013, Pages 803-811

  Lech, MacIej ^a   Rommele, Christoph ^a   Anders, Hans Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

biomarker; dialysis; inflammation; innate immunity; kidney injury

Indexed keywords

AMYLOID P COMPONENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; COMPLEMENT COMPONENT C1Q; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PENTRAXIN; PENTRAXIN 3; TUMOR NECROSIS FACTOR;

ACUTE DISEASE; ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 3Q; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FIBROSING ALVEOLITIS; GLOMERULONEPHRITIS; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION; MORTALITY; NEPHROLOGY; NONHUMAN; PENTRAXIN GENE; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PTX3 GENE; PTX4 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; IMMUNITY, INNATE; KIDNEY DISEASES; NEPHROLOGY; SERUM AMYLOID P-COMPONENT;

EID: 84876012868     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs448     Document Type: Article

References (94)

1. Povoa P, Teixeira-Pinto AM, Carneiro AH. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care 2011; 15: R169
2. Welsch T, Frommhold K, Hinz U et al. Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery 2008; 143: 20-28 (Pubitemid 350266025)
3. Mauri T, Bellani G, Patroniti N et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 2010; 36: 621-629
4. Azzurri A, Sow OY, Amedei A et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005; 7: 1-8 (Pubitemid 40431338)
5. Sprong T, Peri G, Neeleman C et al. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 2009; 31: 28-32
6. Mairuhu AT, Peri G, Setiati TE et al. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol 2005; 76: 547-552 (Pubitemid 40943266)
7. Luchetti MM, Piccinini G, Mantovani A et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119: 196-202 (Pubitemid 30064610)
8. Fazzini F, Peri G, Doni A et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44: 2841-2850 (Pubitemid 34016204)
9. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844 (Pubitemid 28397432)
10. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003; 5: 341-349 (Pubitemid 38898892)
11. Ridker PM. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81-e85
12. Albert CM, Ma J, Rifai N et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-2599 (Pubitemid 34596034)
13. Araujo JP, Lourenço P, Azevedo A et al. Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009; 15: 256-266
14. Paul A, Ko KW, Li L, Yechoor V et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein Edeficient mice. Circulation 2004; 109: 647-655 (Pubitemid 38198873)
15. Teupser D, Weber O, Rao TN et al. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem 2011; 286: 6272-6279
16. Latini R, Maggioni AP, Peri G et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354 (Pubitemid 39407338)
17. Matsui S, Ishii J, Kitagawa F et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010; 210: 220-225
18. Jenny NS, Arnold AM, Kuller LH et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29: 594-599
19. Peri G, Introna M, Corradi D et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation, 2000; 102: 636-641 (Pubitemid 30640663)
20. Brugger-Andersen T, Pönitz V, Kontny F et al. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain. Thromb Haemost 2009; 102: 555-563
21. Latini R, Gullestad L, Masson S et al. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012; 14: 992-999
22. Dubin R, Li Y, Ix JH et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2012; 163: 274-279
23. Garlanda C, Bottazzi B, Moalli F et al. Pentraxins and atherosclerosis: the role of PTX3. Curr Pharm Des 2011; 17: 38-46
24. Ogawa T, Kawano Y, Imamura T et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity 2010: 18: 1871-1874
25. Fisher MA, Taylor GW, Shelton BJ et al. Periodontal disease and other nontraditional risk factors for CKD. Am J Kidney Dis 2008; 51: 45-52 (Pubitemid 350296524)
26. Rule AD, Jacobsen SJ, Schwartz GL et al. A comparison of serum creatinine-based methods for identifying chronic kidney disease in hypertensive individuals and their siblings. Am J Hypertens 2006; 19: 608-614 (Pubitemid 43775857)
27. Cazzavillan S, Ratanarat R, Segala C et al. Inflammation and subclinical infection in chronic kidney disease: a molecular approach. Blood Purif 2007; 25: 69-76 (Pubitemid 46005755)
28. Stenvinkel P. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. Nephrol Ther 2006; 2: 111-119 (Pubitemid 44160677)
29. Janssen U, Bahlmann F, Köhl J et al. Activation of the acute phase response and complement C3 in patients with IgA nephropathy. Am J Kidney Dis 2000; 35: 21-28 (Pubitemid 30027235)
30. Bussolati B, Peri G, Salvidio G et al. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 2003; 170: 1466-1472 (Pubitemid 36139516)
31. Alberti L, Gilardini L, Zulian A et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009; 202: 455-460
32. Miyamoto T, Rashid Qureshi A, Heimbürger O et al. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol 2011; 6: 2785-2791
33. Dubin R, Shlipak M, Li Y et al. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant 2011; 26: 1903-1908
34. Tong M, Carrero JJ, Qureshi AR et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2: 889-897
35. Suliman ME, Yilmaz MI, Carrero JJ et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 976-985
36. Yilmaz MI, Axelsson J, Sonmez A et al. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009; 4: 535-541
37. Suliman ME, Qureshi AR, Carrero JJ et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM 2008; 101: 397-405 (Pubitemid 351619248)
38. Oldani S, Finazzi S, Bottazzi B et al. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients. J Nephrol 2012; 25: 120-126
39. Nishi K, Imamura T, Kitamura K et al. Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease. Ren Fail 2011; 33: 398-404
40. Kanbay M, Ikizek M, Solak Y et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 2011; 33: 325-331
41. Pepys MB, Rademacher TW, Amatayakul-Chantler S et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994; 91: 5602-5606 (Pubitemid 24174376)
42. Enocsson H, Sjöwall C, Skogh T et al. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? Arthritis Rheum 2009; 60: 3755-3760
43. Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 2012; 8: 183-189
44. Theofilopoulos AN, Baccala R, Beutler B et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-336 (Pubitemid 40563172)
45. Kretzschmar D, Hasan G, Sharma S et al. The Swiss cheese mutant causes glial hyperwrapping and brain degeneration in Drosophila. J Neurosci 1997; 17: 7425-7432 (Pubitemid 27413273)
46. Ravizza T, Moneta D, Bottazzi B et al. Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience 2001; 105: 43-53 (Pubitemid 32722092)
47. Tsui CC, Copeland NG, Gilbert DJ et al. Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. J Neurosci 1996; 16: 2463-2478 (Pubitemid 26122671)
48. Schlimgen AK, Helms JA, Vogel H et al. Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system. Neuron 1995; 14: 519-526
49. Hossain MA, Russell JC, O'Brien R et al. Neuronal pentraxin 1: a novel mediator of hypoxic-ischemic injury in neonatal brain. J Neurosci 2004; 24: 4187-4196 (Pubitemid 38620794)
50. Polentarutti N, Bottazzi B, Di Santo E et al. Inducible expression of the long pentraxin PTX3 in the central nervous system. J Neuroimmunol 2000; 106: 87-94 (Pubitemid 30256081)
51. Agnello D, Carvelli L, Muzio V et al. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol 2000; 109: 105-111
52. Breviario F, d'Aniello EM, Golay J et al. Interleukin-1-inducible genes in endothelial cells: cloning of a new gene related to Creactive protein and serum amyloid P component. J Biol Chem 1992; 267: 22190-7
53. Klouche M, Peri G, Knabbe C et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004; 175: 221-228 (Pubitemid 38942901)
54. Mantovani A, Sozzani S, Locati M et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555 (Pubitemid 35223554)
55. Rusnati M, Camozzi M, Moroni E et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-99 (Pubitemid 38879843)
56. Salustri A, Garlanda C, Hirsch E et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004; 131: 1577-1586 (Pubitemid 38559284)
57. Szalai AJ, Agrawal A, Greenhough TJ et al. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999; 37: 265-270 (Pubitemid 29209739)
58. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212 (Pubitemid 14089437)
59. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21(Suppl 2): S43-S47 (Pubitemid 36588649)
60. Goodman AR, Cardozo T, Abagyan R et al. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 1996; 7: 191-202 (Pubitemid 27198077)
61. Shrive AK, Metcalfe AM, Cartwright JR et al. C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP. J Mol Biol 1999; 290: 997-1008 (Pubitemid 29371735)
62. Rubio N, Sharp PM, Rits M et al. Structure, expression, and evolution of guinea pig serum amyloid P component and C-reactive protein. J Biochem 1993; 113: 277-284 (Pubitemid 23100167)
63. Armstrong PB, Swarnakar S, Srimal S et al. A cytolytic function for a sialic acid-binding lectin that is a member of the pentraxin family of proteins. J Biol Chem 1996; 271: 14717-14721 (Pubitemid 26194948)
64. Nauta AJ, Bottazzi B, Mantovani A et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003; 33: 465-473 (Pubitemid 36267612)
65. Tennent GA, Pepys MB. Glycobiology of the pentraxins. Biochem Soc Trans 1994; 22: 74-79 (Pubitemid 24072382)
66. Siebert HC, André S, Reuter G et al. Comparison between intact and desialylated human serum amyloid P component by laser photo CIDNP (chemically induced dynamic nuclear polarization) technique: an indication for a conformational impact of sialic acid. Glycoconj J 1997; 14: 945-949 (Pubitemid 28040015)
67. Ashton AW, Boehm MK, Gallimore JR et al. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol 1997; 272: 408-422 (Pubitemid 27410054)
68. Das T, Mandal C. Variations in binding characteristics of glycosylated human C-reactive proteins in different pathological conditions. Glycoconj J 2004; 20: 537-543 (Pubitemid 41406510)
69. Munoz LE, Lauber K, Schiller M et al. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-289
70. Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-697 (Pubitemid 29289434)
71. Russell AI, Cunninghame Graham DS, Shepherd C et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-147 (Pubitemid 38072141)
72. Sjowall C, Zickert A, Skogh T et al. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther 2009; 11: R188
73. Zandman-Goddard G, Blank M, Langevitz P et al. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 2005; 64: 1698-1702 (Pubitemid 41667142)
74. Rodriguez W, Mold C, Kataranovski M et al. Reversal of ongoing proteinuria in autoimmune mice by treatment with Creactive protein. Arthritis Rheum 2005; 52: 642-650 (Pubitemid 40216331)
75. Rodriguez W, Mold C, Marnell LL et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006; 54: 325-335 (Pubitemid 43122216)
76. Carlucci F, Cook HT, Garg A et al. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum 2010; 62: 245-249
77. Castano AP, Lin SL, Surowy T et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009; 1: 5ra13
78. Li ZI, Chung AC, Zhou L et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Lab Invest 2011; 91: 837-851
79. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factorand IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993; 150: 1804-1812 (Pubitemid 23129656)
80. Vouret-Craviari V, Matteucci C, Peri G et al. Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Infect Immun 1997; 65: 1345-1350 (Pubitemid 27146623)
81. Doni A, Peri G, Chieppa M et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003; 33: 2886-2893 (Pubitemid 37337154)
82. Muller B, Peri G, Doni A et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407 (Pubitemid 32641804)
83. Garlanda C, Hirsch E, Bozza S et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420: 182-186 (Pubitemid 35340122)
84. Gaziano R, Bozza S, Bellocchio S et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004; 48: 4414-4421 (Pubitemid 39434905)
85. Dias AA, Goodman AR, Dos Santos JL et al. TSG-14 transgenic mice have improved survival to endotoxemia and to CLPinduced sepsis. J Leukoc Biol 2001; 69: 928-936 (Pubitemid 32577894)
86. Souza DG, Soares AC, Pinho V et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002; 160: 1755-1765 (Pubitemid 34525655)
87. Rovere P, Peri G, Fazzini F et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigenpresenting dendritic cells. Blood 2000; 96: 4300-4306
88. Bassi N, Ghirardello A, Blank M et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 1704-1710
89. Bottazzi B, Vouret-Craviari V, Bastone A et al. Multimer formation and ligand recognition by the long pentraxin PTX3: similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272: 32817-32823 (Pubitemid 28023616)
90. Lech M, Römmele C, Kulkarni OP et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One 2011; 6: e20118
91. Deban L, Russo RC, Sironi M et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11: 328-334
92. Norata GD, Marchesi P, Pulakazhi Venu VK et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120: 699-708
93. Salio M, Chimenti S, De Angelis N et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117: 1055-1064
94. Argani H, Ghorbanihaghjo A, Panahi G et al. Serum fetuin-A and pentraxin3 in hemodialysis and renal transplant patients. Clin Biochem 2012; 45: 775-779